RecruitingNCT06753838

Choice of Anticoagulant for Primary Hemostasis Studies With PFA200® (Platelet Function Analyser)


Sponsor

Centre Hospitalier Universitaire Dijon

Enrollment

100 participants

Start Date

Jan 21, 2025

Study Type

OBSERVATIONAL

Conditions

Summary

The PFA (platelet function analysis) test is prescribed for the exploration of primary hemostasis and the study of platelet-willebrand factor interaction. It is performed using citrated blood, with technical difficulties and frequent alarms that may be linked to the choice of anticoagulant (citrate). It is proposed to compare the results obtained with a conventional citrate tube and a BAPA tube, which is an anticoagulant used in clinical research and which blocks coagulation by another mechanism that would have less impact on blood platelets.


Eligibility

Min Age: 18 Years

Inclusion Criteria3

  • Person having given their non-opposition
  • Person of legal age
  • Person receiving a haemostasis consultation at the haemophilia and haemorrhagic diseases treatment center followed by a blood sample with a PFA test prescribed by the doctor (the test is not added for the study).

Exclusion Criteria5

  • persons under legal protection (curatorship, guardianship)
  • persons subject to a court protection order
  • pregnant, parturient or breast-feeding women
  • adult incapable or unable to give consent
  • minor

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALSampling of 3 additional BAPA tubes

the 3 additional tubes will be taken at the same time as the blood sample taken for the routine PFA test


Locations(1)

CHU Dijon Bourgogne

Dijon, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06753838


Related Trials